Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis-Reference-Cited by-同舟云学术

Survival benefit of neoadjuvant therapy in patients with non‐metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention‐to‐treat analysis

Published:2019-08-26 Issue:6 Volume:120 Page:976-984
ISSN:0022-4790
Container-title:Journal of Surgical Oncology
language:en
Short-container-title:J Surg Oncol

Author:

Sugimoto Motokazu¹²^ORCID,Takahashi Naoki³,Farnell Michael B.¹,Smyrk Thomas C.⁴,Truty Mark J.¹,Nagorney David M.¹,Smoot Rory L.¹,Chari Suresh T.⁵,Carter Rickey E.⁶,Kendrick Michael L.¹

Affiliation:

1. Division of Hepatobiliary and Pancreas SurgeryMayo Clinic Rochester Minnesota

2. Department of Hepatobiliary and Pancreatic SurgeryNational Cancer Center Hospital East Kashiwa Japan

3. Division of RadiologyMayo Clinic Rochester Minnesota

4. Division of PathologyMayo Clinic Rochester Minnesota

5. Division of Gastroenterology and HepatologyMayo Clinic Rochester Minnesota

6. Division of Biomedical Statistics and InformaticsMayo Clinic Rochester Minnesota

Publisher

Wiley

Subject

Oncology,General Medicine,Surgery

Link